SPOTLIGHT -
Today there are an increasing number of medications for glaucoma. But as yet we are still in the Dark Ages insofar as the cause of this visually disabling disorder.
How amyloid-beta peptide and tau protein demonstrate degeneration
Proteins common to Alzheimer disease play a significant role in glaucoma
Promising avenues could simplify glaucoma management – just in time
Innovative therapies scale up to meet needs of a growing patient population
Sight Sciences announces European launch of OMNI Surgical System Ergo-Series
The company made its CE Mark announcement during the ESCRS Winter Meeting
Iridex Corporation receives European patent on MicroPulse technology
According to the company, the patent further protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields
What do you do when there is no cataract?
Standalone, minimally-invasive glaucoma treatments
Iridex and Imperial College Healthcare NHS Trust announce collaborative MicroPulse TLT study
The partnership establishes a large-scale enrollment platform for research on MicroPulseTransscleral Laser Therapy (TLT)